About CanBas
CanBas is a publicly listed company based in Numazu (Japan) founded in 2000. Drugs for cancer treatment are developed by CanBas. Its website canbas.co.jp draws about 28 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer.
Company details
CanBas is developing drugs for the treatment of cancer. Its lead, CBP501 is a Calmodulin Modulator (phase 1 trials) being developed for resistantrefractory ovarian cancer, NSCLC, and advanced refractory tumors. It is a cell-permeable peptide which targets the G2 checkpoint of the cell cycle. Another candidate, CBS9106 is a small molecule reversible inhibitor of Exportin-1 (XPO1), being developed for advanced refractory cancers.
- Headquarters Numazu, Japan
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website canbas.co.jp
- Social X
- Legal Name Canbas Co., Ltd.
- Net Profit-$8.06 M (USD)-13.03as on Jun 30, 2026
- EBITDA-$8.37 M (USD)-22.43as on Jun 30, 2026
IPO & Listings of CanBas
CanBas is a publicly listed company on the TSE with ticker symbol 4575 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Sep 2009
- Listed onTSE: 4575
- Listed entityCanBas Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3244570002
- Share price756.00 JPY (-2.83% on the day) · 2026-10-14
- Market capitalisation15,336,845,558.00 JPY
- EPS (diluted, trailing year)-66.43 JPY
- Volume (last session)86,400
Financials of CanBas
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | -1.31B JPY | -1.36B JPY | |
| 2025 | -1.16B JPY | -1.11B JPY | |
| 2024 | -1.21B JPY | -1.26B JPY | |
| 2023 | -1.24B JPY | -966.0M JPY | |
| 2022 | -855.6M JPY | -846.4M JPY |
Detailed financial statements for CanBas
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of CanBas
The website of CanBas (canbas.co.jp) receives about 28.2K visits a month and ranks #1,124,423 among all websites worldwide, #1,392 in Biotechnology and Pharmaceuticals.
- Monthly visits28.2K
▼ 7.3% vs previous month
- Unique visitors8.6K
per month
- Global rank#1,124,423
among all websites
- Category rank#1,392
Health · Biotechnology and Pharmaceuticals
- Bounce rate76%
- Pages per visit1.5
- Average visit1 min 01 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with CanBas. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| seikagaku.co.jp | 100% | 15.2K | #1,854,288 | View details | |
pharmadesign.co.jp | pharmadesign.co.jp | 95% | – | ||
| kringle-pharma.com | 94% | 2.5K | #2,077,026 | View details | |
nippongene.com | nippongene.com | 94% | #792,891 | – | |
biobank.co.jp | biobank.co.jp | 94% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 28 similar websites and full traffic analytics for CanBas
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 28 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Canbas
Complete news archive for CanBas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CanBas
CanBas was founded in 2000.
CanBas is headquartered in Numazu, Japan. It is registered at Numazu, Shizuoka, Japan.
CanBas is developing drugs for the treatment of cancer. Its lead, CBP501 is a Calmodulin Modulator (phase 1 trials) being developed for resistantrefractory ovarian cancer, NSCLC, and advanced refractory tumors. It is a cell-permeable peptide which targets the G2 checkpoint of the cell cycle. Another candidate, CBS9106 is a small molecule reversible inhibitor of Exportin-1 (XPO1), being developed for advanced refractory cancers.
Yes, CanBas is publicly traded on TSE under the ticker symbol 4575.